Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.
about
Symptomatic management in multiple sclerosisBrain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trialsNatural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitisDecision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS)Standing up in multiple sclerosis (SUMS): protocol for a multi-centre randomised controlled trial evaluating the clinical and cost effectiveness of a home-based self-management standing frame programme in people with progressive multiple sclerosis.Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple SclerosisTherapeutic Advances and Future Prospects in Progressive Forms of Multiple SclerosisEmerging immunopharmacological targets in multiple sclerosis.Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection").Balance Right in Multiple Sclerosis (BRiMS): a guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with secondary progressive multiple sclerosis: a protocol for a feasibility randomised controUpper Limb Rehabilitation in People With Multiple Sclerosis: A Systematic Review.Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal.Managing Disability in Progressive Multiple Sclerosis.DNA Methylation: a New Player in Multiple Sclerosis.The importance of a multi-disciplinary perspective and patient activation programmes in MS management.Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis.Neuroplasticity-Based Technologies and Interventions for Restoring Motor Functions in Multiple Sclerosis.The effects of mechanical focal vibration on walking impairment in multiple sclerosis patients: A randomized, double-blinded vs placebo study.TNFR1 inhibition with a Nanobody protects against EAE development in mice.Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner.CD4+T cell specific B7-H1 selectively inhibits proliferation of naïve T cells and Th17 differentiation in experimental autoimmune encephalomyelitis.An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial.Pericytes modulate myelination in the central nervous system.Brain endothelial cell expression of SPARCL-1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators in vitro.Nogo-A antibodies enhance axonal repair and remyelination in neuro-inflammatory and demyelinating pathology.Whole-body cryostimulation (cryotherapy) provides benefits for fatigue and functional status in multiple sclerosis patients. A case-control study.Evaluating rehabilitation: An ongoing challenge.Predictors of activity and participation across neurodegenerative conditions: a comparison of people with motor neurone disease, multiple sclerosis and Parkinson's disease.Psychiatric and physical comorbidities and pain in patients with multiple sclerosis.Waterworks.Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions
P2860
Q26779897-6AEF7AD0-7108-4682-BE33-7B5BAEFAB233Q26799233-DBC4E0B6-52A2-4DFF-893B-1A27915CF195Q28071916-8FF36D1D-58FF-445F-811A-EB9FDDD1CAA1Q28085038-679504E5-F3FD-4E1C-B711-D4DFA995EE81Q36008726-D7E3EC98-10AD-4324-9538-42860EE579BEQ36009878-6D0F2BD8-F32E-493B-95E4-F54435C8A4ACQ36247618-68653B69-7C14-4086-8B04-9E493EA4F7F3Q36484443-3EA128E2-2D8B-48E7-BB1F-59B6D0D74181Q37559970-152470EF-DE9C-4B27-9AA3-F1684F9FB2C6Q38379260-F782D2A9-20EF-41C8-9592-E1AA41617B67Q38647807-710DA61B-CA4D-4773-A221-D051E5870CC2Q38690831-1F4E7909-F502-4108-B897-3F59ED2729D8Q38752155-7E2D8865-905F-4ECC-BF84-E5127A97C7D1Q38811069-D3A11D92-BD0D-44E1-95A3-FCF33E9CDF55Q38851770-D3AF21FB-3A4B-46FD-B5BE-01B893EE7F30Q38910577-C160D6E1-4E43-4E99-AED2-7EB6F19A394EQ38937798-E2417D80-F388-421C-A910-8D36B93AAC72Q39027028-3F1E3C2D-9CF7-47BD-B373-7BE37D91A826Q39091406-EA0B46F6-9118-484C-86BF-B39DED46171EQ39447184-0A73CA2E-869B-4EF4-BCEF-AFD632E785E4Q42653357-0B2359A4-32EE-4F1D-ACC1-CA72E0DC312EQ47129747-B2B9AB4A-95FC-483C-86DB-4DB7FF239F3DQ47139579-B5BC1323-0C4A-4A40-A39D-0E2DE9E8C030Q47848180-A6CB3CE1-70B0-42C0-9ABD-BC5A060573B9Q47885821-5B77BD2A-C266-4F85-B7A4-0684AF884A1BQ47928247-2AD0BCB8-9393-408D-BD0E-09BB8BA58110Q48099363-ECB5EA35-F489-4F27-8A66-4A7EA483CED8Q48226160-2E4EA4CF-58B6-4D42-9F42-A36EC7CA1425Q48294644-CA63251B-9D9A-4671-9B08-F7E077C1CBD4Q49873855-E8A550B9-2A6B-49C9-83CC-C099E85C7813Q49901009-152882E4-4E15-4FB8-BD41-F468C40AF6FAQ50533650-9FA4F591-C987-4FA7-9265-81DD896D4C63Q52867608-90254067-601C-47AE-94F3-A011AA5776C6Q53144005-429C14C5-73ED-4DE3-A391-03A69FA31F6BQ58795499-0200B86C-05BC-405A-BFDE-3D72A0D49623
P2860
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Treatment of progressive multi ...... does not, and what is needed.
@en
type
label
Treatment of progressive multi ...... does not, and what is needed.
@en
prefLabel
Treatment of progressive multi ...... does not, and what is needed.
@en
P2093
P1433
P1476
Treatment of progressive multi ...... does not, and what is needed.
@en
P2093
Albert C Lo
Anthony Feinstein
Jenny Freeman
P304
P356
10.1016/S1474-4422(14)70231-5
P577
2015-02-01T00:00:00Z